NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Shares Cross Above 50 Day Moving Average of $0.00

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBYGet Rating) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.00 and traded as high as $2.24. NovaBay Pharmaceuticals shares last traded at $2.06, with a volume of 31,258 shares changing hands.

NovaBay Pharmaceuticals Stock Performance

The stock has a market cap of $3.86 million, a P/E ratio of -0.37 and a beta of 2.69.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBYGet Rating) last posted its earnings results on Monday, November 14th. The biopharmaceutical company reported ($3.50) EPS for the quarter. NovaBay Pharmaceuticals had a negative net margin of 21.09% and a negative return on equity of 18.62%. The company had revenue of $3.83 million during the quarter.

Institutional Trading of NovaBay Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Altium Capital Management LP purchased a new position in NovaBay Pharmaceuticals in the third quarter valued at approximately $121,000. Renaissance Technologies LLC increased its stake in NovaBay Pharmaceuticals by 103.5% in the second quarter. Renaissance Technologies LLC now owns 409,544 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 208,322 shares during the last quarter. Finally, Virtu Financial LLC grew its position in shares of NovaBay Pharmaceuticals by 260.4% during the first quarter. Virtu Financial LLC now owns 163,451 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 118,099 shares during the last quarter.

NovaBay Pharmaceuticals Company Profile

(Get Rating)

NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands.

Featured Articles

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.